Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, Inc. (CDNA) announced that Board member Dr. Hannah Valantine received the 2022 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation during their annual meeting in Boston. Valantine's contributions include pioneering research in heart transplantation and innovations like AlloMap® Heart. Her leadership in the field and efforts to promote health equity in transplantation are highlighted. CEO Reg Seeto praised her for shaping public policy and improving patient care in transplant medicine.
CareDx, Inc. (Nasdaq: CDNA) has announced an expansion to its HeartCare multimodality portfolio, adding an AI prognostic tool for cardiac allograft vasculopathy (CAV) in partnership with OrganX. This development aims to enhance patient stratification by assessing the risk of CAV, a significant cause of heart transplant failure. By integrating this AI tool with existing products like AlloMap® and AlloSure®, CareDx intends to offer a more personalized approach to interventions for improving long-term heart transplant outcomes. The initiative follows positive outcomes from previous AI applications in the KidneyCare portfolio.
CareDx, Inc. (Nasdaq: CDNA) will report its first-quarter 2022 financial results after market close on May 5, 2022. Following the report, company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can join by calling 877-300-8521 for domestic or 412-317-6026 for international access, using Conference ID: 10165254. CareDx specializes in precision medicine solutions for transplant patients, with offerings that include diagnostic testing and digital healthcare solutions.
CareDx, Inc. (Nasdaq: CDNA) announced that CEO Reg Seeto has been appointed Corporate Chair of the ISHLT Foundation's Global Steering Committee. This committee aims to advance innovations in heart and lung transplantation through the "Fostering Excellence Campaign," which will fund vital research and career development awards. CareDx aims to improve outcomes for patients with advanced heart and lung disease, aligning with the ISHLT Foundation's mission. This collaboration highlights CareDx's commitment to enhancing transplant patient care.
CareDx announces the validation of its OTTR Patient Management Software for SMART on FHIR standards, enhancing interoperability in healthcare. This announcement aligns with their presentation of new data on AlloHeme and AlloCell during the Tandem Meetings from April 23-26, 2022, in Salt Lake City, Utah. These innovations are aimed at improving patient monitoring for allogeneic hematopoietic stem cell transplants and therapies. The ACROBAT study will further evaluate AlloHeme's ability in disease relapse detection, promising advancements in patient care.
CareDx, Inc. (Nasdaq: CDNA) announced its collaboration with UC Davis Health to launch a new program named Pluralist. This initiative focuses on improving organ donation and transplantation awareness in underserved communities in California. Through digital education and community engagement, the program aims to address health disparities and increase organ donations, particularly among minority populations who represent a significant share of transplant recipients. CareDx’s contribution to this project underscores its commitment to health equity in transplantation.
CareDx, Inc. (Nasdaq: CDNA) showcased its leadership at the ISHLT Annual Meeting, presenting over 25 oral presentations and posters on heart and lung transplant innovations. Key highlights include interim findings from the Surveillance HeartCare Outcomes Registry (SHORE), which underscore the effectiveness of multimodality assessments in transplant care. CareDx also introduced XenoSure and XenoMap for xenotransplantation research. The company emphasizes the importance of integrating its diagnostic tools for improved patient outcomes and reduced biopsies, demonstrating significant advancements in the field.
CareDx, Inc. (Nasdaq: CDNA) has successfully delivered over 200,000 AlloMap® and AlloSure® test results to more than 30,000 heart transplant patients, showcasing its significant role in the U.S. heart transplant community. The company has been a trusted partner since 2005, with AlloMap being the only FDA-cleared gene-expression profiling test for heart transplants. CareDx’s HeartCare platform, which integrates both AlloMap and AlloSure, is now utilized by over 90% of heart transplant centers in the U.S., reflecting a strong attachment rate of clinical adoption.
CareDx, Inc. (CDNA) announced its participation in the UNOS Transplant Management Forum from April 11-13, 2022, showcasing its TxAccess digital platform designed to expedite the pre-transplant process. The platform facilitates electronic communication and referral processing, significantly reducing errors and time spent on paper-based methods. Medical City Transplant Institute's study highlights improvements in operational workflows and patient management. CareDx's digital tools aim to enhance efficiency and patient experience throughout the transplant journey.
CareDx Hosts Innovative Symposium on Transplant Health
SOUTH SAN FRANCISCO, Calif., April 6, 2022 – CareDx, Inc. (Nasdaq: CDNA) announces its symposium, “Improved Precision with a Multimodality Approach,” at the American Society of Transplantation’s CEoT meeting, April 6-8. The event on April 7 will discuss multimodality surveillance advancements using AlloSure® dd-cfDNA and AlloMap® gene-expression profiling for kidney and lung transplants. NYU Langone Health's abstract on dd-cfDNA stability post-SARS-CoV-2 vaccination reinforces vaccine safety in kidney transplant recipients.
